New strategic funding for innovative therapies
In a strong sign for the local ecosystem, Sensorion, which specializes in treating hearing disorders, has secured a milestone €60 million in funding and welcomed Sanofi as a strategic investor. The funds will enable the company to develop its portfolio of gene therapy products and support several clinical trials for conditions that remain, for the most part, untreatable. In a context of a more selective venture capital market, this transaction helps to reinforce the credibility of the Montpellier-based biotech company.
At the same time, Medincell continues its growth trajectory by raising €48 million from its main shareholders and leading new American and European investors. A pioneer in long-acting injectable treatments, Medincell plans to strengthen its technology platform through targeted innovations and expand partnership opportunities.
Robotics and international strategy: a major industrial milestone
Quantum Surgical is also undergoing a major transformation with the acquisition of the American company NeuWave Medical, a subsidiary of Johnson & Johnson, and the creation of a parent company, Precision IO Group. The merger will notably enable the Epione robotic solution to be combined with NeuWave’s microwave ablation technology, a device already widely used in cancer centers across the United States. The new entity is fully focused on the U.S. market with the objective of becoming a global leader in interventional oncology.
Disruptive innovations in AI and neurotechnologies
The new generation of medtech companies in Montpellier is also confirming its potential. Neurinnov has secured €2.5 million through the highly selective European EIC Accelerator program to accelerate the development of a neurostimulation device designed to restore hand grasping abilities for quadriplegic patients. Meanwhile, AI-Stroke is tackling a major public health challenge: early detection of strokes — the second leading cause of death worldwide — using an AI-powered mobile app and a unique database. The company, which raised $4.6 million in late 2025, has joined Stanford’s StartX acceleration program to speed up its development, particularly in the United States.
Startups supported by Montpellier BIC are bringing promising innovations to the healthcare sector.
Major breakthroughs in chronic and rare diseases
Another company supported by Montpellier BIC, DiappyMed, is driving the digitalization of healthcare with a solution designed to calculate personalized insulin doses for people with diabetes. A fundraising round of €5 million and a strategic partnership with Sanofi support the company's goal of becoming one of the first digital therapies covered by insurance in France by 2026.
In the field of rare diseases, deep tech company Kondree announces a global breakthrough in slowing FSHD (Facioscapulohumeral muscular dystrophy) , with a personalized, clinically validated antioxidant therapy. FSHD is one of the most common forms of muscular dystrophy, for which no curative treatment is available today and therapeutic options aimed at modifying its progression remain limited. Emerging from over twenty years of academic research in Montpellier (PhyMedExp Laboratory and the CHU University Hospital), this approach paves the way for real improvement in the quality of life for patients.
Consolidation and international expansion
The ecosystem is also undergoing strategic restructuring through initiatives such as the merger between KYomed INNOV, and CEISO, which seeks to create a leading player in regulatory support for medical devices.
Additionally, Biodol Therapeutics has secured an international licensing agreement with the Japanese group Kyorin for its innovative treatment of neuropathic pain.
As 2026 unfolds, these announcements offer just a glimpse of the strong momentum building within Montpellier’s healthcare sector, at the junction of research, technological innovation, and public health challenges. This growth is driven by the MedVallée ecosystem, a hub of excellence in global health (One Health).
